Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2016

Open Access 01-12-2016 | Research

Overexpression of proteasomal activator PA28α serves as a prognostic factor in oral squamous cell carcinoma

Authors: Xiaodong Feng, Yuchen Jiang, Liang Xie, Lu Jiang, Jing Li, Chongkui Sun, Hao Xu, Ruinan Wang, Min Zhou, Yu Zhou, Hongxia Dan, Zhiyong Wang, Ning Ji, Peng Deng, Ga Liao, Ning Geng, Yun Wang, Dunfang Zhang, Yunfeng Lin, Ling Ye, Xinhua Liang, Longjiang Li, Gang Luo, Mingye Feng, Juan Fang, Xin Zeng, Zhi Wang, Qianming Chen

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2016

Login to get access

Abstract

Background

Despite recent advances in oral squamous cell carcinoma (OSCC) diagnosis and therapy, disease recurrence remains common and is strongly associated with mortality. It is therefore critical to identify new targets for both treatment and diagnostic purposes. We aimed at investigating the role of PA28α, a proteasomal activator in OSCC.

Methods

The expression of PA28α was examined in a panel of OSCC cell lines and tissues, associated with oncomine analysis. In a large OSCC patient cohort, the prognostic value of PA28α expression was evaluated. Primary clinical end points were recurrence-free and overall survival rate. Functional involvement of PA28α in OSCC was examined in both in vitro and in vivo models upon specific siRNA knockdown.

Results

PA28α was found to be overexpressed in OSCC cell lines and tumor tissues. High expression of PA28α was significantly associated with recurrence and poorer overall survival. Specific knockdown of PA28α inhibited OSCC cell proliferation, migration, invasion in vitro and reduced the growth of OSCC xenografts in vivo. Multivariate Cox regression analyses revealed PA28α as independent prognostic predictors.

Conclusions

These results suggest that PA28α is involved in OSCC oncogenesis and may serve as a potential prognostic factor.
Appendix
Available only for authorised users
Literature
1.
2.
Lewin F, Norell SE, Johansson H, Gustavsson P, Wennerberg J, Biorklund A, Rutqvist LE. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: a population-based case-referent study in Sweden. Cancer. 1998;82:1367–75.
3.
Scully C. Oral squamous cell carcinoma; from an hypothesis about a virus, to concern about possible sexual transmission. Oral oncology. 2002;38:227–34.CrossRefPubMed
4.
Rechsteiner M, Hill CP. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends in cell biology. 2005;15:27–33.CrossRefPubMed
5.
Masters EI, Pratt G, Forster A, Hill CP. Purification and analysis of recombinant 11S activators of the 20S proteasome: Trypanosoma brucei PA26 and human PA28 alpha, PA28 beta, and PA28 gamma. Methods in enzymology. 2005;398:306–21.CrossRefPubMed
6.
Li X, Lonard DM, Jung SY, Malovannaya A, Feng Q, Qin J, Tsai SY, Tsai MJ, O'Malley BW. The SRC-3/AIB1 coactivator is degraded in a ubiquitin- and ATPindependent manner by the REGgamma proteasome. Cell. 2006;124:381–92.
7.
Li X, Amazit L, Long W, Lonard DM, Monaco JJ, O'Malley BW. Ubiquitin- and ATP-independent proteolytic turnover of p21 by the REGgamma-proteasome pathway. Mol Cell. 2007;26:831–42.CrossRefPubMed
8.
Li L, Dang Y, Zhang J, Yan W, Zhai W, Chen H, Li K, Tong L, Gao X, Amjad A, Ji L, Jing T, Jiang Z, Shi K, Yao L, Song D, Liu T, Yang X,Yang C, Cai X, Xu W, Huang Q, He J, Liu J, Chen T, Moses RE, Fu J, Xiao J, Li X. REGγ is critical for skin carcinogenesis by modulating the Wnt/β-catenin pathway. Nat Commun. 2015;6:6875.
9.
Groettrup M, Soza A, Eggers M, Kuehn L, Dick TP, Schild H, Rammensee HG, Koszinowski UH, Kloetzel PM. A role for the proteasome regulator PA28alpha in antigen presentation. Nature. 1996;381:166–8.
10.
Murata S, Udono H, Tanahashi N, Hamada N, Watanabe K, Adachi K, Yamano T, Yui K, Kobayashi N, Kasahara M, Tanaka K, Chiba T. Immunoproteasome assembly and antigen presentation in mice lacking both PA28alpha and PA28beta. EMBO J. 2001;20:5898–907.
11.
Longuespee R, Boyon C, Castellier C, Jacquet A, Desmons A, Kerdraon O, Vinatier D, Fournier I, Day R, Salzet M. The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: evidence from mass spectrometry profiling. Histochem Cell Biol. 2012;138:141–54.
12.
Lemaire R, Menguellet SA, Stauber J, Marchaudon V, Lucot JP, Collinet P, Farine MO, Vinatier D, Day R, Ducoroy P, Salzet M, Fournier I. Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J Proteome Res. 2007;6:4127–34.
13.
Wang Z, Feng X, Liu X, Jiang L, Zeng X, Ji N, Li J, Li L, Chen Q. Involvement of potential pathways in malignant transformation from oral leukoplakia to oral squamous cell carcinoma revealed by proteomic analysis. BMC genomics. 2009;10:383.
14.
Wang Z, Jiang L, Huang C, Li Z, Chen L, Gou L, Chen P, Tong A, Tang M, Gao F. Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma, vol. 7: ASBMB, 2008:1639.
15.
Talbot SG, Estilo C, Maghami E, Sarkaria IS, Pham DK, Oc P, Socci ND, Ngai I, Carlson D, Ghossein R, Viale A, Park BJ, et al. Gene expression profiling allows distinction between primary and metastatic squamous cell carcinomas in the lung. Cancer research. 2005;65:3063–71.
16.
Pyeon D, Newton MA, Lambert PF, den Boon JA, Sengupta S, Marsit CJ, Woodworth CD, Connor JP, Haugen TH, Smith EM, Kelsey KT, Turek LP, et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer research. 2007;67:4605–19.PubMedCentralCrossRefPubMed
17.
Tan F, Zhu H, Tao Y, Yu N, Pei Q, Liu H, Zhou Y, Xu H, Song X, Li Y, Zhou Z, He X, Zhang X, Pei H. Neuron navigator 2 overexpression indicates poor prognosis of colorectal cancer and promotes invasion through the SSH1L/cofilin-1 pathway. J Exp Clin Cancer Res. 2015;34(1):117.
18.
Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM. Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res. 2004;64(15):5232–6.
19.
Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, Elbashir S, Geick A, Hadwiger P, Harborth J. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432:173–8.
20.
Wang Z, Jiang L, Huang C, Li Z, Chen L, Gou L, Chen P, Tong A, Tang M, Gao F, Shen J, Zhang Y, et al. Comparative proteomics approach to screening of potential diagnostic and therapeutic targets for oral squamous cell carcinoma. Mol cell proteomic. 2008;7:1639–50.
21.
Haorah J, Heilman D, Diekmann C, Osna N, Donohue Jr TM, Ghorpade A, Persidsky Y. Alcohol and HIV decrease proteasome and immunoproteasome function in macrophages: implications for impaired immune function during disease. Cell Immunol. 2004;229:139–48.
22.
Frisan T, Levitsky V, Masucci MG. Variations in proteasome subunit composition and enzymatic activity in Blymphoma lines and normal B cells,”. Int J Cancer. 2000;88:881–8.CrossRefPubMed
23.
Murata S, Udono H, Tanahashi N, Hamada N, Watanabe K, Adachi K, Yamano T, Yui K, Kobayashi N, Kasahara M, Tanaka K, Chiba T. Immunoproteasome assembly and antigen presentation in mice lacking both PA28α and PA28β. EMBO J. 2001;20:5898-907.
24.
Groettrup M, van den Broek M, Schwarz K, Macagno A, Khan S, de Giuli R, Schmidtke G. Structural plasticity of the proteasome and its function in antigen processing. Crit Rev Immunol. 2001;21:339–58.
25.
Shachar I, Karin N. The dual roles of inflammatory cytokines and chemokines in the regulation of autoimmune diseases and theirclinical implications. J Leukoc Biol. 2011;93:51–61.CrossRef
26.
Ahn JY, Tanahashi N, Akiyama K, Hisamatsu H, Noda C, Tanaka K, Chung CH, Shibmara N, Willy PJ, Mott JD PJ, et al. Primary structures of two homologous subunits of PA28, a gamma interferon-inducible protein activator of the 20S proteasome. FEBS Lett. 1995;366:37–42.
27.
Tanahashi N, Yokota K, Ahn JY, Chung CH, Fujiwara T, Takahashi E, DeMartino GN, Slaughter CA, Toyonaga T, Yamamura K, Shimbara N, Tanaka K. Molecular properties of the proteasome activator PA28 family proteins and \( \gamma \)-interferon regulation,”. Genes Cells. 1997;2:195–211.
28.
Zhang M, Ishii K, Hisaeda H, Murata S, Chiba T, Tanaka K, Li Y, Obata C, Furue M, Himeno K. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein. Immunology. 2004;112:567–74.
29.
Miyagi T, Tatsumi T, Takehara T, Kanto T, Kuzushita N, Sugimoto Y, Jinushi M, Kasahara A, Sasaki Y, Hori M, Hayashi N. Impaired expression of proteasome subunits and human leukocyte antigens class I in human colon cancer cells. J Gastroenterol Hepatol. 2003;18:32–40.
30.
Ritz U, Momburg F, Pilch H, Huber C, Maeurer MJ, Seliger B. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol. 2001;19:1211–20.PubMed
31.
Kloetzel PM, Ossendorp F. Proteasome is required for class I-restricted presentation by Fcgamma receptor-mediated endocytosis in primary biliary cirrhosis. Curr Opin Immunol. 2004;16:76–81.CrossRefPubMed
32.
33.
De Leo A, Matusali G, Arena G, Di Renzo L, Mattia E. Epstein-Barr virus lytic cycle activation alters proteasome subunit expression in Burkitt's lymphoma cells. Biol Chem. 2010;391:1041–6.PubMed
34.
Kim K, Brush JM, Watson PA, Cacalano NA, Iwamoto KS, McBride WH. Epidermal growth factor receptor vIII expression in U87 glioblastoma cells alters their proteasome composition, function, and response to irradiation. Mol Cancer Res. 2008;6:426–34.PubMedCentralCrossRefPubMed
35.
Tsihlis ND, Kapadia MR, Vavra AK, Jiang Q, Fu B, Martinez J, Kibbe MR. Nitric oxide decreases activity and levels of the 11S proteasome activator PA28 in the vasculature. Nitric Oxide. 2012;27:50–8.
36.
Yagi H, Tan W, Dillenburg-Pilla P, Armando S, Amornphimoltham P, Simaan M, Weigert R, Molinolo AA, Bouvier M, Gutkind JS. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Science signaling. 2011;4:ra60.
Metadata
Title
Overexpression of proteasomal activator PA28α serves as a prognostic factor in oral squamous cell carcinoma
Authors
Xiaodong Feng
Yuchen Jiang
Liang Xie
Lu Jiang
Jing Li
Chongkui Sun
Hao Xu
Ruinan Wang
Min Zhou
Yu Zhou
Hongxia Dan
Zhiyong Wang
Ning Ji
Peng Deng
Ga Liao
Ning Geng
Yun Wang
Dunfang Zhang
Yunfeng Lin
Ling Ye
Xinhua Liang
Longjiang Li
Gang Luo
Mingye Feng
Juan Fang
Xin Zeng
Zhi Wang
Qianming Chen
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2016
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-016-0309-z

Other articles of this Issue 1/2016

Journal of Experimental & Clinical Cancer Research 1/2016 Go to the issue

Erratum

Erratum to: Detection of ATM germline variants by the p53 mitotic centrosomal localization test in BRCA1/2-negative patients with early-onset breast cancer

Research

Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin

Research

JunB promotes cell invasion, migration and distant metastasis of head and neck squamous cell carcinoma

Research

The leukemogenic fusion gene MLL-AF9 alters microRNA expression pattern and inhibits monoblastic differentiation via miR-511 repression

Research

Sustained delivery of siRNA/PEI complex from in situ forming hydrogels potently inhibits the proliferation of gastric cancer

Research

Sam68 reduces cisplatin-induced apoptosis in tongue carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits